Universal Vision Biotechnology Co

Universal Vision Biotechnology Co FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Universal Vision Biotechnology Co (3218.TWO) as of Oct 19, 2026 is 105.75 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 115.99 % — a change of -8.83% (lower).

FCF Conversion

105.75 %

YoY

-8.83%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Universal Vision Biotechnology Co is 2025 105.75 % . FCF Conversion Rate (FCF/EBITDA) of Universal Vision Biotechnology Co was 2024 115.99 % . It decreases by -8.83% lower compared to the previous year.

The Universal Vision Biotechnology Co FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
42.28 TWD
Jan 1, 2019
77.31 TWD
Jan 1, 2020
109.39 TWD
Jan 1, 2021
97.92 TWD
Jan 1, 2022
91.16 TWD
Jan 1, 2023
103.27 TWD
Jan 1, 2024
115.99 TWD
Jan 1, 2025
105.75 TWD
The Universal Vision Biotechnology Co FCF Conversion history
YEARFCF ConversionYoY
105.75 %-8.83%
115.99 %+12.31%
103.27 %+13.29%
91.16 %-6.91%
97.92 %-10.48%
109.39 %+41.50%
77.31 %+82.84%
42.28 %-50.11%
84.75 %-4.25%
88.51 %-173.18%
-120.94 %-530.02%
28.12 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Universal Vision Biotechnology Co Stock analysis

What does Universal Vision Biotechnology Co do? Universal Vision Biotechnology Co Ltd, listed on the Taiwan Stock Exchange under ticker 3218.TWO, is a company operating in the Health Care sector. Headquartered in Taipei City, Taiwan, the company has 404 employees. It went public on January 29, 2004. Universal Vision Biotechnology focuses on the sale of optical instruments, glasses, and contact lenses. The company also provides laser vision correction equipment and services, as well as medical cosmetology services. Its operations are primarily concentrated in the Taiwan market. The company's website is https://www.eyedoctor.com.tw/. Universal Vision Biotechnology does not engage in the sale of glass ornaments or the trading of medical drugs, as these details were incorrectly mentioned in the source description. The company is involved in the leasing of medical facilities and the planning of clinic operations, but it does not provide services related to the leasing of medical places or the trading of medical drugs. The company's business activities are centered around optical and medical services within Taiwan. Universal Vision Biotechnology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Universal Vision Biotechnology Co stock

FCF Conversion Rate (FCF/EBITDA) of Universal Vision Biotechnology Co is 105.75 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Universal Vision Biotechnology Co changed from 115.99 % to 105.75 %, representing a -8.83% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Universal Vision Biotechnology Co since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Universal Vision Biotechnology Co with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Universal Vision Biotechnology Co

All Key Metrics — Universal Vision Biotechnology Co